Agios Pharmaceuticals, Inc. (FRA:8AP)

Market Cap	1.45B -22.7%
Revenue (ttm)	46.02M +48.0%
Net Income	-351.57M
EPS	-6.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	24.20
Previous Close	23.20
Day's Range	24.20 - 24.20
52-Week Range	19.70 - 38.80
Beta	n/a
RSI	57.25
Earnings Date	Feb 12, 2026

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 540
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AP

Financial Performance

Financial numbers in USD